3rd Circ. Affirms Class Cert. In Suboxone Antitrust Case
Law360 (July 28, 2020, 6:20 PM EDT) -- A federal judge in eastern Pennsylvania correctly focused on common harm in certifying a direct purchaser class suing Indivior Inc. over its allegedly anti-competitive actions aimed at boosting the cost of opioid addiction treatment Suboxone, the Third Circuit ruled Tuesday.
The decision by a three-judge panel upheld U.S. District Judge Mitchell S. Goldberg's finding that Burlington Drug Co. Inc. and two other purchasers from the 72 that sued were suitable class representatives for the case, which sought only to recover excess costs caused by Indivior's alleged market-control efforts.
Indivior was spun off from Reckitt Benckiser Pharmaceuticals Inc. in 2014.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!